ArticleCancer medicine2021

Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.

Yaning Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.